The changes of radiotherapy in Lithuania: infrastructure, utilization rate, and cost

Background. The aim of this study was to evaluate radiation therapy (RT) productivity, capacity, and cost in Lithuania.

Materials and methods. An electronic questionnaire was prepared and sent to the country’s RT centres. The data was collected for the years 2011–2014. The early data of the RT infrastructure was obtained from the QUARTS Project (2001).

Results. In Lithuania the external beam RT was applied to 32.6% of new cancer cases (non-melanomatous skin cancer and benign conditions were excluded). In 2014, RT was more frequently applied for breast and prostate carcinomas, 23 and 20%, respectively. The country owned 11 units of linear accelerators (linacs) and this accounts for 3.7 linacs per one million population. 3D conformal RT is the standard approach in all four RT centres in Lithuania. IMRT practices were established in three centers and VMAT or stereotactic RT in two of them. 73% of linacs were capable of IGRT, while only 27% were equipped with CBCT. The average linac workload was 567 patients per year and showed a 10% decrease compared with the 2011 data. During a ten-year period, the average cost per patient for RT treatment increased 7.6 times – from EUR 129 to 974. The reimbursement system in Lithuania is not favourable for application of RT.

Conclusions. During the recent thirteen years, RT services in Lithuania have dramatically improved, but we are still behind the average of European countries and benchmark rates. It is important to continue optimising the efficiency of RT services, and further evidence-based studies on RT infrastructure assessment and planning are needed.

Keywords: radiotherapy in Lithuania, utilization rate, equipment, workload, cost

INTRODUCTION

In Lithuania, as in all developed and developing countries, the number of new cancer cases increases every year – in 10 years (2002–2012) the number of oncology patients increased by 23%; the index of new cases of cancer per 100 thousand citizens increased by more than 42% (1). It is partially linked to the ageing population – in 2012, 52% of new cancer cases in Lithuania were diagnosed for patients 55–74 years of age and 29.5% for patients older than 75 (1). It is expected that in 2030 almost 1/3 (28.9%) of citizens will be elderly people (2). These population changes will further contribute to cancer incidence and the demand for RT services over the next decades.
Approximately half of the cancer patients require radiation treatment at some time during the course of their illness. Some recent studies (3–5) suggest that the optimal RT utilisation rate varies from 40.6% in England to 53.4% in Poland. But since 2005 most of the publications quote the results of the Delaney et al. (6) study which indicated that 52.3% of all people with notifiable malignancies would require RT at some stage during the course of their disease. These recommendations were reviewed in 2013, and the evidence-based guidelines suggest that in Australia RT is the treatment of choice for 48.3% of notifiable cancers (7).

The last assessment of the RT situation in Lithuania was performed in 2001, in the QUARTS Project (Quantification of Radiation Therapy Infrastructure and Staffing Needs), initiated by the European Society for Therapeutic Radiology and Radiation Oncology (ESTRO) (8, 9). Over the past decade, there have been enormous changes in the delivery of RT from two-dimensional and three-dimensional (3D) to intensity-modulated radiotherapy (IMRT) and image-guided radiotherapy (IGRT) treatments using the greatly improved accuracy of CT simulation, multileaf collimators, etc. These complicated methods require more and more material resources, but according to some studies (10, 11) the costs of external RT constitute only 5% of the total costs for oncology services. However, an important factor influencing the choice of treatment modalities is the reimbursement system in Lithuania.

Without doubt, since the beginning of this century, RT has undergone many qualitative and structural changes. Projects, funded by the European Union in Lithuania, helped to purchase the major part of the diagnostic and treatment equipment. During the recent thirteen years, the number of linacs in Lithuania has increased 5.5 times; all cobalt machines were dismantled and not used any more.

The aim of this study was to estimate the situation of RT in Lithuania and to review the changes of RT productivity, equipment, workload, and RT service cost over the 13-year period from 2001 to 2014; to compare the current situation with other countries; and to predict the future demand for linacs until the year 2025. This is necessary for the rational planning of our financial resources in the future, and thereby ensuring the accessibility and quality of the RT services provided for patients. This is because the results of the QUARTS Project seem to have had a valuable impact on the government decisions.

MATERIALS AND METHODS

An electronic questionnaire was prepared and sent to all 4 RT centres in Lithuania. The data were collected for the calendar years of 2011 and 2014. The questionnaire consisted of 4 blocks of questions: general information about patients (numbers of patients treated, cancer types); RT methods applied; equipment owned; costs of RT services (only in the questionnaire of 2011).

The response rate was 100%. In order to identify contradictory data or to obtain missing information, an individual, standardised verbal survey was carried out (contacting by phone). The data published on the websites of the institutions were used as well.

Information about the RT situation in Lithuania in 2001 was obtained from the QUARTS Project participants.

Data of other countries from the published literature and the results of the ESTRO QUARTS (8) and HERO projects (12), as well as documents and technical reports published in the official websites of international organisations (ESTRO, World Health Organisation (WHO), International Atomic Energy Agency (IAEA), etc.) were used. We selected the literature and reports relevant to the objective and methodology.

The article includes external beam RT data; we did not include benign indications, non-melanoma skin cancer, and paediatric cancer. The calculations of the external RT application level in the country included only primary patients. The RT utilisation rate is described as the number of new cases of cancer treated using RT per year, divided by the number of newly registered cases of cancer during that year. The numbers of new cases of cancer were obtained from the data of the Lithuanian Cancer Registry (the last report presents 2012 data) (1).

The assessment of the workload for equipment, the number of patients, was calculated as the sum of primary and repeat therapy patients who received RT services in the calendar year.

Evaluating the RT cost, we used the cost structure and calculation methods mentioned in the literature (13, 14).

The assessment of linacs demand in 2025 was based on the Australian (7, 15, 16) model (414 pts/
linac/year; additional 10% capacity in linac numbers to negate increase in the waiting times for treatment; a 25% re-treatment rate). For cancer incidence projections, the Globocan database was used (17).

RESULTS

Current situation of external beam radiotherapy in Lithuania
RT services in Lithuania are provided by 4 public healthcare institutions, two of which are established in the major cities and have 69% of patients per year. The other 2 RT centres are about three to four times smaller, regarding the number of patients treated as well as the number of linacs.

On the average, one RT centre in the country provides treatment for 1,702 patients per year (pts/year). It is estimated that 64% of RT services are delivered within the outpatient setting.

In 2012 the number of new cancer cases was 17,734 (1). Approximately 32.6% of all newly diagnosed patients were treated with external beam RT (non-melanomatous skin cancer and benign conditions were excluded) alone or in combination with other treatment modalities.

In 2014 the five most frequent cancers (66%) treated by RT were the following: breast, prostate, gynaecological, head and neck, lung cancers (Table 1). In comparison with the 2001 data, prostate and breast cancer patients treated by RT increased, especially prostate patients – more than 80%; other cancer patients decreased.

Equipment
Figure 1 shows an overview of RT equipment units in 2001–2014. In 2014 there were 11 linacs in the country: two major oncology centres owned 4 units each and the two smaller had 1 and 2 units, respectively, i.e. the largest centres had 73% of the entire RT infrastructure. IMRT practices were established in three centers and volumetric modulated arc therapy (VMAT) or stereotactic RT in two of them. 73% of linacs were capable of IGRT, while only 27% were equipped with kilovoltage cone-beam computed tomography (CBCT).

There was a decrease in the number of orthovoltage treatment units, from 11 in 2001 to 4 in 2014. Currently these machines are only used for treatments of some skin tumours and other superficial lesions. The RT centres owned 4 simulators. There

| Years | Breast | Prostate | Gynecological | Head and neck | Lung | Others |
|-------|--------|----------|---------------|---------------|------|--------|
| 2001  | 19.4   | 3.9      | 11.9          | 10.6          | 10.3 | 43.9   |
| 2014  | 23.3   | 19.9     | 8.7           | 6.8           | 7.3  | 34     |
| Change* | 16.7   | 80.4     | −36.8         | −55.9         | −41.1| −29.1  |

* Formula: (2014 data − 2001 data)/2014 data * 100%.
was an average of 0.36 simulators per linac unit. In 2014, there were 11 units of planning systems, all centres implemented 3D planning, three of them IMRT. In 2014, 100% of the patients had computerised treatment plans as compared to the year 2001 when this index was only about 30%.

Cost of radiotherapy
The costs of RT departments were evaluated according to cost inputs used by other studies (13, 14), and the results were compared with those of the year 2001 (Table 2).

Both in 2011 and in 2001, the major cost drivers included the cost of equipment (purchases, depreciation, maintenance) and personnel salaries. In 2001, personnel costs were the most important cost component of an RT department, while in 2011 equipment costs were most important (78% of all these costs were for linacs purchasing and maintenance). Maintenance of equipment accounted for about 17% of all costs within the equipment category.

In total, the average cost per patient for RT treatment was EUR 974, that is 7.5 times more than that in the year 2001 (in 2001 it was EUR 129). The cost varies widely from one delivery method to the next one. Also, it depends on the institution size, e.g. in small institutions (departments treating <1,000 pts/year) the cost per patient was higher by more than 80%. So, looking from an economic point of view, the cost effectiveness applies to RT centres that treat more than 1,000 new patients annually, as is shown in other countries (9).

Reimbursement system
Lithuania has a compulsory health insurance system, which means that residents of Lithuania are obliged to obtain health insurance coverage (i.e. pay compulsory health insurance contributions). With respect to the insured, the State guarantees healthcare services compensated by the Compulsory Health Insurance Fund.

The Ministry of Health establishes the appraisement for radiotherapy services provided by health institutions. The costs of expensive examinations and procedures performed during the episode of the active in-patient treatment are included in the total cost of healthcare service and are not reimbursed separately. An average reimbursement by the health institution for one treated patient with 3D conformal RT is 571 EUR; and for IMRT it is EUR 860. Obviously, institutions suffer losses providing RT services.

DISCUSSION
Comparing the current survey data with the data from Western countries or published optimal benchmarks, it is clear that the Lithuanian RT infrastructure is still below the average. According to our data, the actual RT utilisation rate in Lithuania was 32.6%, and it is relatively low when compared with the developed countries (Fig. 2) (4, 15, 18). When compared with the Australian evidence-based estimation of the optimal RT utilization rate of 48.3% (7), or with the benchmark

| Table 2. Average annual costs of RT department by separate cost groups (%) |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
|                  | Buildings | Equipment | Salaries | Materials | Overhead | Total |
| Lithuania, 2001  | 5         | 39        | 43       | 4          | 9        | 100   |
| Lithuania, 2011  | 2         | 46        | 39       | 1          | 12       | 100   |

Fig. 2. Actual utilisation rates of radiation therapy (%)
rate of the neighbouring country Poland (53.4%) (5), there is a significant shortfall between the optimal rate and the proportion of patients currently treated with RT. The HERO study (19) shows that the optimal utilization rate for Lithuania should be 51.5%.

The most common tumour sites treated by RT were breast and prostate cancer cases. The numbers of these cancer sites increased during the last 10 years, but others (gynaecological, head and neck, lung cancer) decreased. This could be influenced by the following: the changes in cancer morbidity trends of some cancer sites (e.g. large increase of prostate cases; on the other hand, lung cancer cases decreased or stabilised); activity of cancer prevention and control programmes; implementing new, modern, and accurate RT technologies; changing treatment techniques and recommendations; the preference of the physician for one therapeutic option over alternatives; internal policy of health institutions and benchmarking; etc.

In Lithuania there were 3.7 linacs per million inhabitants. It does not meet the guidelines as developed by IAEA (20) and ESTRO (8, 9). Western European countries reached this index ten years ago (21). However, according to the data of the HERO study (19), Lithuania surpasses such Eastern European countries as Estonia and Poland, but falls behind the Czech Republic, Hungary, and Slovenia.

ESTRO recommends that Lithuania has 4.6 linacs per million population (9), which is 14 units. Only 79% of this level were reached in 2014. However, the overview of the latest reports and recommendations for linac workload (11, 16) concludes that the number of treatment units within Lithuania does not ensure accessibility of RT services and treatment quality.

For planning RT needs for 2025, three linacs demand scenarios were estimated based on the RT utilisation rate (Table 3). This prognosis was made on the basis of the Australian principal calculation criteria (15, 16). We did not find an official national prognosis of new cancer cases, so we used the Globocan database (17). It predicted a significant reduction of new cancer cases in 2025. This raises some suspicion. In order to make more precise linac requirements in the future, more accurate calculations are required, including cancer trends for each cancer site.

| RT utilisation rate | Linacs required in 2025 |
|---------------------|------------------------|
| Current rate 32.6%  | 14                     |
| Optimal rate 48.3%  | 21                     |
| Halfway rate 40.5%  | 18                     |

The workload of linacs during recent years has been significantly reduced due to the increasing number of machines. But the workload exceeds the median number in European countries (419 treatment courses per MV unit) (12), international recommendations, and the data of other countries (18, 21–23) (Table 4).

| Recommendation | Facts                  |
|----------------|------------------------|
| ESTRO          |                        |
| UK, 2002       | 456                    |
| Spain, 2007    | 476                    |
| The Netherlands, 2010 | 451         |
| Poland, 2011   | 678                    |
| Lithuania, 2014| 567                    |

The cost of RT depends on treatment modality, treatment intent (for cure or palliation), localisation of the primary site of cancer, stage, and other factors. In this survey, we calculated the average RT treatment costs in RT centres per calendar year. Our result is much lower than the average cost calculated by other studies, e.g. Ploquin and Dunscombe performed cost metaanalysis in which the mean normalized cost in 2005 was EUR 3.239 (14); in the recent Ireland study, the cost of traditional RT for rectal cancer in 2012 was EUR 3.609 (24). Certainly, there are calculation errors due to methodological differences, but we can see common tendencies and make a comparison and come to preliminary conclusions. The investigation data shows that the reimbursement system in Lithuania is improper and does not cover treatment expenses. So, health institutions are not willing to provide RT services, and this could be one of the reasons for the low RT utilisation rate.

In order to lower RT treatment costs, it is necessary to increase the number of outpatients. Despite the fact that in the literature RT is described as a cost-effective treatment, it requires a high initial
capital investment and has high on-going operating costs. Consequently, radiation treatment should be centralized in regional cancer centres (with more than 1,000 RT pts/year), especially for middle income countries as Lithuania and where distances to RT centres are not longer than 200 km.

In conclusion, during the recent thirteen years, RT services in Lithuania have dramatically improved, but we are still behind the average of European countries and benchmark rates. This potential need for additional new equipment and the workforce required to support it represents a significant challenge over the coming years and needs to feed into trust capital planning and workforce strategies as early as possible. The reimbursement system in the country is not in favour of RT centres. In order to raise the RT utilization rate, the reimbursement mechanism has to be reviewed and optimised. We think that this overview of the Lithuanian RT infrastructure will help to assess the current situation and continue the successful development of the RT services by increasing their accessibility and high quality.

Received 1 February 2016
Accepted 21 March 2016

References

1. Lithuanian Cancer Registry [Internet]. Vilnius: National Cancer Institute [cited 2015 Jun 23]. Available from: http://www.nvi.lt/index.php?-1413089819
2. Official Statistics Portal [Internet]. Vilnius: Statistics Lithuania [cited 2015 Jun 16]. Available from: http://osp.stat.gov.lt/en/home
3. Round CE, Williams MV, Mee T, Kirkby NF, Cooper T, Hoskin P, Jena R. Radiotherapy demand and activity in England 2006–2020. Clin Oncol. 2013; 25: 522–30.
4. Mackillop WJ, Kong W, Brundage M, Hanna TP, Zhang-Salomons J, McLaughlin PY, Tyldesley S. A comparison of evidence-based estimates and empirical benchmarks of the appropriate rate of use of radiation therapy in Ontario. Int J Radiat Oncol Biol Phys. 2015; 91: 1099–107.
5. Borras JM, Barton JM, Grau C, Corral J, Verhoven R, Lemmens V, et al. The impact of cancer incidence and stage on optimal utilization of radiotherapy: Methodology of a population based analysis by the ESTRO-HERO project. Radiother Oncol. 2015 Jul; 116(1): 45–50. doi: 10.1016/j.radonc.2015.04.021. Epub 2015 May 19.
6. Delaney G, Jacob S, Featherstone C, Barton M. The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer. 2005; 104: 1129–37.
7. Barton MB, Jacob S, Shafiq J, Wong K, Thompson SR, Hanna TP, Delaney GP. Estimating the demand for radiotherapy from the evidence: a review of changes from 2003 to 2012. Radiother Oncol. 2014; 112: 140–4.
8. Slotman BJ, Cottier B, Bentzen SM, Heeren G, Lievens Y, van den Bogaert W. Overview of national guidelines for infrastructure and staffing of radiotherapy. ESTRO-QUARTS: Work package 1. Radiother Oncol. 2005; 75: 349–54.
9. Bentzen SM, Heeren G, Cottier B, Slotman B, Glimelius B, Lievens Y, van den Bogaert W. Towards evidence-based guidelines for radiotherapy infrastructure and staffing needs in Europe: the ESTRO QUARTS project. Radiother Oncol. 2005; 75: 355–65.
10. Norlund A. Costs of radiotherapy. Acta Oncol. 2003; 42: 411–5.
11. Radiotherapy Services in England 2012 [Internet]. Department of Health Cancer [cited 2015 Jul 28]. Available from: http://ncat.nhs.uk/sites/default/files/work-docs/Radiotherapy-Services-in-England-2012.pdf
12. Grau C, Defourny N, Malicki J, Dunscombe P, Borras JM, Coffey M, et al. Radiotherapy equipment and departments in the European countries: Final results from the ESTRO-HERO survey. Radiother Oncol. 2014; 112: 155–64.
13. Lievens Y, van den Dogaert W, Kesteloot K. Activity-based costing: a practical model for cost calculation in radiotherapy. Int. J Radiat Oncol Biol Phys. 2003; 57: 522–35.
14. Ploquin NP, Dunscombe PB. The cost of radiation therapy. Radiother Oncol. 2008; 86: 217–23.
15. Radiation Oncology Tripartite Committee. Planning for the Best: Tripartite National Strategic Plan for Radiation Oncology 2012–2022, Version 1. 2012 [Internet]. Australia: The Royal Australian and New Zealand College of Radiologists; 2012 [cited 2015 Jul 11]. Available from: http://www.radiationoncology.com.au/supporting-docs/PlanningForTheBest-TripartiteNationalStrategicPlanForRadiation-Oncology.2012-2022.pdf
16. Radiotherapy Services in NSW Strategic Plan to 2016 [Internet]. NSW Department of Health; 2010 [cited 2015 Jul 11]. Available from: http://www.health.nsw.gov.au/pubs/2010/pdf/radiotherapy_services_plan.pdf

17. Globocan 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012 [Internet]. WHO [cited 2015 May 2]. Available from: http://globocan.iarc.fr/

18. Slotman BJ, Vos PH. Planning of radiotherapy capacity and productivity. Radiother Oncol. 2013; 106: 266–70.

19. Borras JM, Lievens Y, Dunscombe P, Coffey M, Malicki J, Corral J, et al. The optimal utilization proportion of external beam radiotherapy in European countries: An ESTRO-HERO analysis. Radiother Oncol. 2015 Jul; 116(1): 38–44. doi: 10.1016/j.radonc.2015.04.018. Epub 2015 May 14.

20. International Atomic Energy Agency. Setting Up a Radiotherapy Program: Clinical, Medical Physics, Radiation Protection and Safety Aspects. Vienna: IAEA; 2008.

21. The Royal College of Radiologists (Great Britain). Equipment, workload and staffing for radiotherapy in the UK 1997–2002. BFCO (03)3. London: Royal College of Radiologists; 2003.

22. Palacios Eito A, Espinosa Calvo M, Manas Ruenda A, de Las Heras M. Radiation oncology: Future needs and equipment. Current situation in Spain. Clin Transl Oncol. 2008; 10: 478–85.

23. Reinfruss M, Byrski E, Malicki J. Radiotherapy facilities, equipment, and staffing in Poland: 2005–2011. Rep Pract Oncol Radiother. 2013; 18: 159–72.

24. Hanly P, Ó Céilleachair A, Skally M, O’Neill C, Sharp L. Direct costs of radiotherapy for rectal cancer: a microcosting study. BMC Health Serv Res. 2015; 15: 184.

Ramunė Mineikytė, Ernestas Janulionis, Vydmantas Atkočius, Laimonas Jaruševičius, Aista Plieskienė, Jonas Gečas

LIETUVOS SPINDULINĖS TERAPIJOS POKYČIAI: INFRASTRUKTŪRA, TAIKYMO DAŽNIS, IŠLAIDOS

Tyrimo tikslas – įvertinti Lietuvos spindulinės terapijos (ST) pajégumus, produktyvumą ir išlaidas.

Tyrimo medžiaga ir metodai. Parengtas ir į visus šalies ST centrus išsiųstas elektroninis klausimynas. Rinkti ir pateikiami 2011–2014 m. duomenys. Ankstesni duomenys apie ST infrastruktūrą buvo gauti iš QUARTS projekto (2001 m.).

Rezultatai. 32,6 % naujai diagnozuotų onkologinių atvejų gavo išorinį ST gydymą (išskyrus nemelanominio odos vėžio ir gerybinius onkologinius atvejus). 2014 m. ST dažniausiai taikyta krūties ir prostatos vėžiui gydyti – atitinkamai 23 ir 20 %. Šalyje veikė 11 linijinių greitintuvų (LG), t. y. 1 mln. gyventojų teko 3,7 LG. Visuose keturiuose Lietuvos ST centruose taikomos standartinės terapijos metodas – 3D konforminė ST. IMRT buvo taikoma trijuose centrnuose, volumetriškai moduliuoto intensyvumo ST ir stereotaktinė ST – dviejose. Nors 73 % LG turėjo IGRT galimybę, bet tik 27 % LG turėjo kūginio pluošto kompiuterinius tomografus. Su vienu LG per 2014 m. vidutiniškai buvo gydoma 567 pacientų. LG apkrova, palyginti su 2011 m. duomenimis, sumazėjo 10 %. ST gydymo išlaidos vientiems pacientams per dešimt metų išaugo 7,6 karto – nuo 129 iki 974 Eur, tačiau gydymo kompensavimo sistema Lietuvoje nepalanki taikyti spindulinę terapiją – gydymo įstaigos, taikydamos šį metodą, patiria finansinių nuostolių.

Išvados. Per pastaruoju metų Lietuvos ST paslaugos pagerėjo, tačiau vis dar arsiliekame nuo Europos šalių vidurkio ir standartų. Todėl būtina tęsti ST paslaugų optimizaciją ir pradėtus mokslinius tyrimus vertinant ir planuojant ST infrastruktūrą.

Raktažodžiai: spindulinė terapija Lietuvoje, taikymo dažnis, įranga, apkrova, išlaidos